Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Instruments, Software), Application (Respiratory Diseases, HAIs, Cancer, STDs, Hepatitis), Technology (RT-PCR, INAAT), End User (Clinics, Hospitals, ICUs) - Global Forecast to 2028

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKETS COVERED
  • 1.3.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
  • 1.3.2 GEOGRAPHIC SCOPE
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 STUDY LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES
  • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3.2 TOP-DOWN APPROACH
  • FIGURE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 LIMITATIONS
• 2.8 RISK ASSESSMENT
  • 2.8.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
• 2.9 RECESSION IMPACT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

• FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
• FIGURE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
• FIGURE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 11 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

• 4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
  • FIGURE 13 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
• 4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028
  • FIGURE 14 ASSAYS & KITS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
• 4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2023 VS. 2028
  • FIGURE 15 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028
  • FIGURE 16 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2023 VS. 2028
  • FIGURE 17 PHYSICIANS' OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
• 4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
    • 5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
    • 5.2.1.3 Growing awareness of the early detection of infectious diseases
    • 5.2.1.4 Increasing use of POC diagnostic tests
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.2.2 High capital investments and low cost-benefit ratio
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing
    • 5.2.3.2 Growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase product launch cycle
    • 5.2.4.2 Introduction of alternative technologies
• 5.3 PRICING ANALYSIS
  • TABLE 1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
• 5.4 PATENT ANALYSIS
  • FIGURE 20 PATENT ANALYSIS FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS (JANUARY 2013-DECEMBER 2022)
  • 5.4.1 LIST OF KEY PATENTS
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
• 5.6 SUPPLY CHAIN ANALYSIS
  • FIGURE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS: SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • 5.7.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 2 PORTER'S FIVE FORCES ANALYSIS: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 PESTLE ANALYSIS
• 5.10 REGULATORY ANALYSIS
  • TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
    • 5.10.1.6 Africa
• 5.11 TRADE ANALYSIS
  • TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
• 5.12 TECHNOLOGY ANALYSIS
• 5.13 KEY CONFERENCES AND EVENTS, 2023-2024
  • TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 24 REVENUE SHIFT IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
  • TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
  • 5.15.2 BUYING CRITERIA
  • FIGURE 26 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS
  • TABLE 12 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS

6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
• 6.2 ASSAYS & KITS
  • 6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH
  • TABLE 14 KEY ASSAYS & KITS AVAILABLE IN MARKET
  • TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021-2028 (USD MILLION)
• 6.3 INSTRUMENTS & ANALYZERS
  • 6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN MARKET
  • TABLE 16 KEY INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
  • TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021-2028 (USD MILLION)
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND
  • TABLE 18 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
  • TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
  • TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
• 7.2 RT-PCR
  • 7.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
  • TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021-2028 (USD MILLION)
• 7.3 INAAT
  • 7.3.1 COST BENEFITS OF INAAT TO BOOST DEMAND
  • TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021-2028 (USD MILLION)
• 7.4 OTHER TECHNOLOGIES
  • TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
  • TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 8.2 RESPIRATORY DISEASES
  • 8.2.1 RISING DEMAND FOR EARLY DIAGNOSIS AND DETECTION OF RESPIRATORY DISEASES TO DRIVE GROWTH
  • TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021-2028 (USD MILLION)
• 8.3 SEXUALLY TRANSMITTED DISEASES
  • 8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR DETECTION OF STDS TO FAVOR MARKET GROWTH
  • TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021-2028 (USD MILLION)
• 8.4 HOSPITAL-ACQUIRED INFECTIONS
  • 8.4.1 RISING BURDEN OF MRSA TO SUPPORT GROWTH
  • TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (USD MILLION)
• 8.5 CANCER
  • 8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET
  • TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
• 8.6 HEPATITIS
  • 8.6.1 INCREASING CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO BOOST GROWTH
  • TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2028 (USD MILLION)
• 8.7 GASTROINTESTINAL DISORDERS
  • 8.7.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO PROPEL MARKET
  • TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
• 8.8 OTHER APPLICATIONS
  • TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
• 8.9 COVID-19
  • 8.9.1 DECLINING CASES OF COVID-19 TO HINDER MARKET GROWTH
  • TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)

9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER

• 9.1 INTRODUCTION
  • TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 9.2 PHYSICIANS' OFFICES
  • 9.2.1 FASTER RESULTS ASSOCIATED WITH POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH
  • TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES, BY REGION, 2021-2028 (USD MILLION)
• 9.3 HOSPITALS & ICUS
  • TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021-2028 (USD MILLION)
  • 9.3.1 SEPSIS
    • 9.3.1.1 Growing need for quick diagnosis and treatment to favor market growth
  • 9.3.2 GASTROENTERITIS
    • 9.3.2.1 Growing incidence of gastroenteritis cases in emergency departments to propel growth
  • 9.3.3 MENINGOENCEPHALITIS
    • 9.3.3.1 Severity of disease and need for early detection to drive demand
  • 9.3.4 OTHER DISEASES
• 9.4 RESEARCH INSTITUTES
  • 9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTIC TESTS IN GENOMICS RESEARCH TO CONTRIBUTE TO MARKET GROWTH
  • TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
• 9.5 OTHER END USERS
  • TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 10.1 INTRODUCTION
  • TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 10.2 NORTH AMERICA
  • 10.2.1 RECESSION IMPACT: NORTH AMERICA
  • FIGURE 27 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 44 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2.2 US
    • 10.2.2.1 Growing prevalence of infectious diseases to drive market
  • TABLE 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 48 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2.3 CANADA
    • 10.2.3.1 Rising government initiatives to propel market growth in coming years
  • TABLE 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 52 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.3 EUROPE
  • 10.3.1 RECESSION IMPACT: EUROPE
  • TABLE 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 56 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 57 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.2 GERMANY
    • 10.3.2.1 Increasing healthcare expenditure to drive market growth in Germany
  • TABLE 58 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 59 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 60 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 61 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.3 UK
    • 10.3.3.1 Increasing prevalence of infectious diseases to fuel growth
  • TABLE 62 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 63 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 64 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 65 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising R&D expenditure in France to boost market
  • TABLE 66 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 67 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 68 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 69 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.5 ITALY
    • 10.3.5.1 Adoption of advanced diagnostic technologies to favor growth
  • TABLE 70 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 71 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 72 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 73 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
  • TABLE 74 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 75 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 76 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 77 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.7 REST OF EUROPE
  • TABLE 78 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 79 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 80 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 81 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.4 ASIA PACIFIC
  • 10.4.1 RECESSION IMPACT: ASIA PACIFIC
  • FIGURE 28 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • TABLE 82 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 85 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.2 CHINA
    • 10.4.2.1 Growing public access to modern healthcare to drive market growth
  • TABLE 87 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 88 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 89 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 90 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.3 JAPAN
    • 10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
  • TABLE 91 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 92 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 93 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 94 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing private & public investments in healthcare system to support market growth
  • TABLE 95 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 96 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 97 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 98 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.5 REST OF ASIA PACIFIC (ROAPAC)
  • TABLE 99 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 100 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 101 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 102 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.5 LATIN AMERICA
  • 10.5.1 LOW PER CAPITA HEALTH SPENDING TO RESTRAIN MARKET GROWTH
  • 10.5.2 RECESSION IMPACT: LATIN AMERICA
  • TABLE 103 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 104 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 105 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 106 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH
  • 10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA
  • TABLE 107 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 108 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 109 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 110 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 STRATEGIES OF KEY PLAYERS
  • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
  • TABLE 111 OVERVIEW OF STRATEGIES DEPLOYED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
• 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2018-2022)
• 11.4 MARKET SHARE ANALYSIS
  • FIGURE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
  • TABLE 112 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE: DEGREE OF COMPETITION
• 11.5 COMPANY EVALUATION QUADRANT
  • 11.5.1 LIST OF EVALUATED VENDORS
  • 11.5.2 STARS
  • 11.5.3 EMERGING LEADERS
  • 11.5.4 PERVASIVE PLAYERS
  • 11.5.5 PARTICIPANTS
  • FIGURE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2022
• 11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2022)
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 STARTING BLOCKS
  • 11.6.3 RESPONSIVE COMPANIES
  • 11.6.4 DYNAMIC COMPANIES
  • FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022
• 11.7 COMPETITIVE BENCHMARKING
  • 11.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
  • FIGURE 33 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
  • TABLE 113 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY REGIONAL FOOTPRINT
  • TABLE 114 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
  • TABLE 115 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
• 11.8 COMPETITIVE SCENARIO
  • 11.8.1 PRODUCT LAUNCHES & APPROVALS
  • TABLE 116 KEY PRODUCT LAUNCHES & APPROVALS
  • 11.8.2 DEALS
  • TABLE 117 KEY DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
• (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
• 12.1.1 ABBOTT LABORATORIES
• TABLE 118 ABBOTT LABORATORIES: BUSINESS OVERVIEW
• FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
• 12.1.2 F. HOFFMANN-LA ROCHE LTD.
• TABLE 119 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
• FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
• 12.1.3 BIOMERIEUX SA
• TABLE 120 BIOMERIEUX SA: BUSINESS OVERVIEW
• FIGURE 36 BIOMERIEUX SA: COMPANY SNAPSHOT (2022)
• 12.1.4 DANAHER CORPORATION
• TABLE 121 DANAHER CORPORATION: BUSINESS OVERVIEW
• FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
• 12.1.5 QIAGEN N.V.
• TABLE 122 QIAGEN N.V.: BUSINESS OVERVIEW
• FIGURE 38 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
• 12.1.6 QUIDELORTHO CORPORATION
• TABLE 123 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
• FIGURE 39 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
• 12.1.7 CO-DIAGNOSTICS, INC.
• TABLE 124 CO-DIAGNOSTICS INC.: BUSINESS OVERVIEW
• FIGURE 40 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
• 12.1.8 BIOCARTIS NV
• TABLE 125 BIOCARTIS NV: BUSINESS OVERVIEW
• FIGURE 41 BIOCARTIS NV: COMPANY SNAPSHOT (2022)
• 12.1.9 MERIDIAN BIOSCIENCE, INC.
• TABLE 126 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
• FIGURE 42 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2022)
• 12.1.10 THERMO FISHER SCIENTIFIC INC.
• TABLE 127 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
• FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
• *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
• 12.2 OTHER PLAYERS
  • 12.2.1 LUCIRA HEALTH, INC.
  • 12.2.2 CUE HEALTH
  • 12.2.3 OPGEN, INC.
  • 12.2.4 BINX HEALTH, INC.
  • 12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
  • 12.2.6 GENOMADIX
  • 12.2.7 VISBY MEDICAL, INC.
  • 12.2.8 QUIKPATH PTE. LTD.
  • 12.2.9 MD-BIO
  • 12.2.10 QUANTUMDX GROUP LTD.
  • 12.2.11 AIDIAN OY
  • 12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC.
  • 12.2.13 LABSYSTEMS DIAGNOSTICS OY
  • 12.2.14 AKONNI BIOSYSTEMS
  • 12.2.15 CURETIS N.V.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 AVAILABLE CUSTOMIZATIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS